Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses

BACKGROUND: Romidepsin is a structurally unique, potent, bicyclic class 1 selective histone deacetylase inhibitor approved by the US Food and Drug Administration for the treatment of patients with cutaneous T-cell lymphoma who have received ≥ 1 prior systemic therapy and patients with peripheral T-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Coiffier, Bertrand, Pro, Barbara, Prince, H Miles, Foss, Francine, Sokol, Lubomir, Greenwood, Matthew, Caballero, Dolores, Morschhauser, Franck, Wilhelm, Martin, Pinter-Brown, Lauren, Padmanabhan Iyer, Swaminathan, Shustov, Andrei, Nielsen, Tina, Nichols, Jean, Wolfson, Julie, Balser, Barbara, Horwitz, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4016573/
https://www.ncbi.nlm.nih.gov/pubmed/24456586
http://dx.doi.org/10.1186/1756-8722-7-11

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4016573/
https://www.ncbi.nlm.nih.gov/pubmed/24456586
http://dx.doi.org/10.1186/1756-8722-7-11

Ejemplares similares